...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: BIO-Europe Presentation
Reply New Message
Prev Message Back To Forum Threaded View Next Message

Previous presentations have a slide up front titled "Share Structure Profile" that lists the Enterprise Value Estimate (eg for the last one: $350 to $375MM USD, $2.50 to $3.00 USD/share).

For this presentation, that's been replaced with a slide titled "Zenith Profile" does not list the Enterprise Value Estimate.

3 Recommendations
Reply New Message
Prev Message Back To Forum Threaded View Next Message
Share
Share
New Message
Please login to post a reply